Why Does Retatrutide Increase Heart Rate? The Glucagon Effect Explained

Introduction

Most people who start a GLP-1 medication notice nausea, reduced appetite, or slower digestion. These are expected effects of the drug class. What catches some retatrutide users off guard is something different: a noticeable increase in resting heart rate.

This isn't a random side effect. It has a specific pharmacological cause that sets retatrutide apart from every other approved or investigational GLP-1 medication — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Understanding why it happens, how large the increase is, and when it matters clinically makes this a manageable and predictable finding rather than a cause for alarm.

The answer is retatrutide's third receptor target: glucagon.

What the Phase 2 Data Shows

The retatrutide Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine, 2023) is the primary published source for quantifying the heart rate effect. The trial enrolled 338 adults and tested doses from 1mg to 12mg weekly over 48 weeks.

Key findings on heart rate:

Heart rate increased in a dose-dependent manner — higher doses produced larger increases. At the highest doses studied (8mg and 12mg), participants experienced mean resting heart rate increases of approximately 5–7 beats per minute (bpm) above baseline.

The NEJM paper directly states: "The heart rate increased with retatrutide treatment in a dose-dependent manner, peaking at 24 weeks, followed by a decline at 36 and 48 weeks; the increases were similar to those reported with other incretin-based therapies."

Two important details from this description:

Peak at week 24: The increase is not constant. It reaches its maximum during dose escalation — typically around the time patients reach or approach maintenance dose — then partially declines at weeks 36 and 48, while still remaining above baseline.

"Similar to other incretin-based therapies" with an important caveat: The NEJM paper compares the effect broadly to other GLP-1 drugs. However, published data confirms retatrutide's increase is meaningfully larger than what semaglutide or tirzepatide produce, for a specific mechanistic reason.

Comparing Heart Rate Increases Across Medications

‍
The additional ~3 bpm above tirzepatide's effect is attributable to retatrutide's glucagon receptor component. Neither semaglutide nor tirzepatide activates glucagon receptors, which is precisely why their heart rate effects are smaller.

No specific heart rate figures from TRIUMPH-4 or TRIUMPH-1 Phase 3 trials have been published in topline results to date. The Phase 2 data remains the primary quantitative reference.

The Mechanism: Why Glucagon Speeds Up the Heart

The heart rate increase is not a side effect in the traditional sense — it is a direct, predictable pharmacological consequence of glucagon receptor activation. Understanding the mechanism requires understanding what glucagon does in the body.

Glucagon's cardiac role:

Glucagon is primarily known as a counter-regulatory hormone that raises blood glucose when levels fall. But glucagon receptors are also expressed in cardiac tissue, where their activation has two well-documented effects:

A positive chronotropic effect — increasing heart rate — and a positive inotropic effect — increasing the force of heart contractions. When glucagon binds to cardiac receptors, it activates adenylyl cyclase, which converts ATP into cyclic AMP (cAMP). Elevated cAMP in cardiac cells increases both the rate and force of contraction.

This is not a hypothesis. It is established cardiac pharmacology, documented in the NEJM paper: "Glucagon and GLP-1 can exert positive chronotropic and inotropic effects on the heart."

GLP-1 also contributes:

GLP-1 receptor activation by itself produces a modest chronotropic effect — this is why semaglutide and tirzepatide raise heart rate by 1–4 bpm. Retatrutide adds glucagon receptor activation on top of this baseline effect.

The total heart rate increase seen with retatrutide (~5–7 bpm) therefore reflects the combined contribution of both GLP-1 and glucagon receptor activation on cardiac tissue — a pharmacological signature unique to this drug class.

An important nuance from the NEJM paper:

The paper notes that the mechanism "may further amplify heart rate elevation" through the glucagon receptor, while acknowledging this is consistent with the known pharmacology rather than proven in direct mechanistic studies specific to retatrutide. The overall mechanistic conclusion is well-supported but should be understood as consistent with established biology rather than definitively isolated in retatrutide-specific cardiac experiments.

Is a 5–7 bpm Increase Clinically Significant?

For most patients without pre-existing cardiovascular conditions, a 5–7 bpm resting heart rate increase is clinically mild.

To put it in context: a resting heart rate of 70 bpm rising to 76 bpm is within normal physiological variation and does not represent pathological tachycardia. The Phase 2 trial reported no serious cardiac events directly attributed to the heart rate elevation.

However, a published expert review of the Phase 2 data in Expert Opinion on Investigational Drugs (2023) noted: "Heart rate was increased by up to 6.7 beats/min by retatrutide, which may be detrimental and offset some of the benefits of weight loss" — particularly for patients with cardiovascular comorbidities.

This balanced assessment is important. For the average patient losing 28% of body weight with parallel improvements in blood pressure, lipids, and metabolic health, the net cardiovascular picture is strongly positive. The heart rate increase is a manageable downside in a treatment whose benefits substantially outweigh it for most patients.

When it matters more:

For patients with normal resting heart rate and no pre-existing cardiac conditions, the increase is generally well-tolerated and not a reason to avoid treatment.

How the Effect Behaves Over Time

The temporal pattern of heart rate increase is clinically useful to know in advance:

Weeks 1–24 (escalation phase): Heart rate gradually increases as doses rise. The increase peaks around week 24 — typically when patients approach or reach their maintenance dose.

Weeks 24–48 (post-peak): Even without dose reduction, heart rate partially declines from its peak. The NEJM paper documents this fall at weeks 36 and 48, while remaining above baseline.

After stopping treatment: Heart rate increase fully reverses upon discontinuation, as the drug clears over 3–4 weeks (retatrutide half-life approximately 6–7 days).

This temporal pattern — peak during escalation, partial decline at maintenance, full reversal after stopping — is predictable and manageable. It is not a permanently elevated state.

How This Compares to Retatrutide's Cardiovascular Benefits

The 5–7 bpm heart rate increase exists alongside substantial cardiovascular improvements:

From TRIUMPH-4 Phase 3 data: systolic blood pressure fell by 14.0 mmHg at 12mg. From TRIUMPH-1: systolic blood pressure fell by 12.3 mmHg at 80 weeks, triglycerides reduced by up to 41.0%, and non-HDL cholesterol fell by up to 24.2%.

The net cardiovascular risk picture for most retatrutide patients is therefore: lower blood pressure, improved lipid profile, reduced systemic inflammation (lower hsCRP) — alongside a modest heart rate elevation. For the majority of patients, the balance is strongly favorable.

TRIUMPH-Outcomes — retatrutide's long-term cardiovascular outcomes trial — will eventually provide definitive data on whether retatrutide reduces major cardiovascular events. Results are expected 2028–2029. Until then, the indirect evidence from cardiovascular risk factor improvements is promising.

For a full overview of what retatrutide's cardiovascular data shows, see our cardiovascular outcomes guide.

Practical Implications for Patients

If you are considering retatrutide or following its development:

A resting heart rate increase of 5–7 bpm is expected and normal during treatment. It is not a sign that something is wrong with the medication or your heart.

The increase peaks around week 24 and partially declines thereafter. If you find it uncomfortable during escalation, discuss dose timing or escalation rate with your prescriber — though formal dose-reduction protocols for heart rate specifically have not been published.

If you have a known heart condition — particularly arrhythmia, heart failure, or resting tachycardia — flag this specifically when discussing retatrutide with a cardiologist or prescribing physician before treatment begins. These populations were excluded from TRIUMPH trials.

If you are transitioning from tirzepatide to retatrutide (which some patients may do after approval in 2028), expect a noticeable additional heart rate effect from adding glucagon receptor activation. Allow 4–6 weeks at a stable dose before drawing conclusions about your cardiovascular response.

Conclusion

Retatrutide's heart rate increase is not a mystery or a red flag — it is a predictable, mechanistically explained consequence of activating a receptor that neither semaglutide nor tirzepatide targets. Glucagon is chronotropic. Activating glucagon receptors in cardiac tissue raises heart rate. At 5–7 bpm, the magnitude is small and generally well-tolerated in patients without pre-existing cardiac conditions.

Weighed against 28.3–28.7% weight loss, a 14 mmHg blood pressure drop, 41% triglyceride reduction, and a 75.8% reduction in knee pain in OA patients, the heart rate increase is a manageable pharmacological trade-off for most of the patients retatrutide is designed to treat.

The patients who need to take it most seriously are those with arrhythmias, pre-existing tachycardia, or heart failure — populations that were excluded from TRIUMPH trials and for whom safety data remains limited.

Sources

• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023;389:514–526. (Primary source for heart rate data)
• Ilkiw JL, Charman SA, Gao X, et al. "Retatrutide showing promise in obesity (and type 2 diabetes)." Expert Opinion on Investigational Drugs, 2023;32(11):997–1001. doi: 10.1080/13543784.2023.2283020. (Expert analysis citing 6.7 bpm figure)
• Eli Lilly press release: TRIUMPH-4 Phase 3 topline results. December 11, 2025.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• Giblin K, Kaplan LM, Somers VK, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026;28(1):83-93.